By 2033, the global hepatitis B diagnostic testing market will expand at a CAGR of 6.5% to reach US$1,744.26 million

Cutting-edge hepatitis B diagnostic technology facilitates early detection, driving preventive healthcare in the United States and regional demand.

Newark, Del., Oct. 10, 2023 (GLOBE NEWSWIRE) — The global hepatitis B diagnostic testing market is expected to be valued at $872.5 million 2023, driven by health checks and government initiatives.This trend is expected to create new opportunities for the global market, with an expected CAGR of 6.5% Between 2023 and 2033.The estimated valuation is approximately US$1,744.26 million By 2033.

The continuous advancement in diagnostic technology has greatly impacted the hepatitis B diagnostic testing market. The development of detection methods such as enzyme immunoassay and nucleic acid detection has improved the accuracy, sensitivity and specificity of detection.

The most common cause of liver disease and cancer is hepatitis B. The relevance of liver health has led to an increase in the number of people seeking preventive health care, especially those with risk factors including a genetic history or specific behaviors for hepatitis B. Regular hepatitis B testing allows for early detection and treatment, which can help prevent problems and liver damage. Regional demand across the United States is increasing due to an emphasis on preventive care and living well.

Request a sample copy of the Hepatitis B Diagnostic Tests Market report now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-1332

Key Takeaways from the Hepatitis B Diagnostic Test Market Study

• Hepatitis B diagnostic testing market continues to expand Compound annual growth rate is 4.5% From 2018 to 2022.

• The U.S. hepatitis B diagnostic testing market is expected to exceed 34.7% Market share in 2023.

• China is expected to take 23.2% Share of global hepatitis B diagnostic tests market by 2023.

• Japan’s hepatitis B diagnostic testing market will remain stable by the end of 2023 7.1% global market share.

• France Hepatitis B Diagnostic Testing Market Expected to Grow by 2023 8%.

• By 2023, the hepatitis B diagnostic test market in the UK is expected to reach 7.8% market share.

• It is expected that the market share of enzyme-linked immunoassay kits in 2023 will reach 71.90%.

• Hospital business will expand rapidly Compound annual growth rate of 6.2% throughout the forecast period.

The story continues

“Promoting hepatitis B diagnostic testing through public health programs, increased liver screening, and healthcare marketing has increased awareness and diagnosis rates,” comments Sabyasachi Ghosh (Vice President, Future Market Insights, Inc.)

Competitive Landscape of Hepatitis B Diagnostic Testing Market:

Manufacturers often explore new geographical regions to increase their market share. They develop distributed networks and partnerships with healthcare organizations and providers around the world. Manufacturers can gain access to untapped customer base by diversifying into new markets and areas with high hepatitis B incidence rates.

To ensure that their products comply with local norms and laws, companies can also apply for regulatory licenses and certifications in other countries.

Learn how-to details with just one click!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1332

The top ten players in the Hepatitis B Diagnostic Tests market are:

1. Bio-Rad Laboratories Ltd.

2. DIASOLIN LIMITED.

3. Abbott Laboratories

4. Meridian Bioscience

5. bioMérieux

6. Vista Diagnostics International

7. Bioman Laboratories Ltd.

8. J.Mitra Ltd.

9. Siemens Medical Solutions USA, Inc.

10. general biologics corp.

Product Portfolio of Hepatitis B Diagnostic Testing Market:

• Abbott Laboratories is a broad-service healthcare company that has been involved in the production of pharmaceuticals, particularly antiviral drugs. They have created drugs to treat chronic hepatitis B in the past. One example is the drug “Hepsera” (generic name: adefovir dipivoxil), which is used in certain individuals to prevent the reproduction of the hepatitis B virus.

• “Viread” produced by Gilead Sciences is one of the drugs commonly used to treat hepatitis B. Tenofovir disoproxil fumarate (TDF), the active ingredient in Viread, is an antiviral drug designed to prevent hepatitis B virus (HBV) replication in patients with chronic hepatitis B infection.

Get exclusive market insights – buy now!
https://www.futuremarketinsights.com/checkout/1332

Provide more valuable insights:

Future Market Insights provides an unbiased analysis of the global Hepatitis B Diagnostic Tests market, providing historical data from 2018 to 2022 as well as forecast statistics from 2023 to 2033.

To understand the opportunities in the Hepatitis B Diagnostic Tests market, based on product type (enzyme immunoassay kits, point-of-care testing kits), end user (hospitals, clinics, diagnostic centers, home care), end user (hospitals, clinics, diagnostic centers , home care) and seven major regions (North America, Latin America, Western Europe, Eastern Europe, South Asia and the Pacific, East Asia, and the Middle East and Africa (MEA)).

Hepatitis B Diagnostic Test Market Segment Analysis:

By product type:

By end user:

• Hospital

• Clinic

• diagnostic center

• home care

By region:

• North America

• Latin America

• Western Europe

• Eastern Europe

• South Asia and the Pacific

• East Asia

• Middle East and Africa

Healthcare Sector About Future Market Insights

Future Market Insights’ Healthcare domain offers expert analysis, time-saving research and strategic advice designed to deliver real insights and accurate results to help clients across the globe. With over 100 reports and over 1 billion data points, the team has been analyzing the industry with clarity in over 50 countries for over a decade. The team provides a brief analysis of key trends, including the competitive landscape, margins and R&D efforts.

author

Sabyasachi Ghosh (Vice President, Future Market Insights, Inc.) has over 12 years of experience in the healthcare, medical device and pharmaceutical industries. His curiosity and analytical skills have helped shape his research career.

It comes naturally to them to identify their clients’ key challenges and design powerful, hypothesis-based solutions that empower them to make strategic decisions. His primary expertise lies in the areas of market entry and expansion strategy, feasibility studies, competitive intelligence and strategic transformation.

Sabyasachi holds a degree in microbiology, has numerous publications, and has been cited in journals such as Journal of Mobile Health, ITN Online, and Spine Surgery News.

Check out related coverage in the healthcare space:

Diagnostic Imaging Services Market: Diagnostic imaging is the process of imaging the human body with the help of various imaging services. These services include a variety of technologies, processes and equipment used to monitor, diagnose, screen and treat medical conditions for effective medical intervention.

Portable medical devices market: is expected to register a CAGR of 10.7% during the forecast period. The market is expected to generate market revenue of US$163.84 billion by 2033.

Diagnostic exosome biomarkers market: expected to reach $196.8 million by 2023. Diagnostic exosome biomarker sales are expected to grow significantly at a CAGR of 16.3% between 2023 and 2033.

Diagnostic Imaging Markers Market: Diagnostic imaging markers are biomarkers or biometric features that are detectable in images. The image is relevant to the diagnosis of a certain disease in the patient.

diagnosis.

About Future Market Insights (IMF)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award winner, member of the Greater New York Chamber of Commerce) provides deep insights into the drivers driving market demand. FMI is a leading global provider of market intelligence, consulting services, consulting and events for the packaging, food and beverage, consumer technology, healthcare, industrial and chemicals markets. FMI has a large team of more than 5,000 analysts worldwide, providing global, regional and local expertise on diverse sectors and industry trends in more than 110 countries.

contact us:

Nandini Singh Savarani

Future Market Insights Company
Christiana Inc., 200 Continental Avenue,
Suite 401, Newark, DE – 19713, United States
Phone: +1-845-579-5705
Sales inquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter | Blog | YouTube